StockStory Sees Pfizer Strength, Flags Danaher and Integer Risks
The publisher points to Pfizer’s revenue scale and improving adjusted operating profits, while citing growth and margin concerns at two peers.
Key takeaways
- StockStory cited Pfizer’s $63.7 billion revenue base and rising adjusted operating profits.
- The publisher flagged Danaher’s lower adjusted operating margin and Integer’s forecast sales growth of 1.5%.
StockStory identified Pfizer as a healthcare company with competitive advantages, while flagging Danaher and Integer Holdings as risky. The publisher cited Pfizer’s $63.7 billion revenue base and rising adjusted operating profits.
For Danaher, StockStory pointed to disappointing organic revenue over the past two years and a 7.8-percentage-point decline in adjusted operating margin over five years. It also said earnings per share fell 1.6% annually over that period.
The publisher said Integer’s sales grew 6.1% annually over the past two years, but estimated sales growth of 1.5% over the next 12 months. It also cited the company’s $1.84 billion revenue base as a disadvantage against larger competitors.
This article was produced with the help of AI technology. Source: Yahoo Finance
